- 1 Title: Time-Varying Risk of Death After SARS-CoV-2-Infection in Long-Term Care Facility
- 2 Residents: A Matched Cohort Study
- 3 Short title: Time-Varying Mortality After SARS-CoV-2
- 5 **Authors:** Marcel Ballin, MSc^{1*}^, John P.A. Ioannidis, MD, DSc^{2,3}^, Jonathan Bergman,
- 6 PhD¹, Miia Kivipelto, MD, PhD^{4,5}, Anna Nordström, MD, PhD^{1,6,7}, Peter Nordström, MD,
- 7 PhD¹

- 8 ^ Indicating shared first authorship and equal contribution.
- 9 Affiliations: ¹Department of Community Medicine and Rehabilitation, Unit of Geriatric
- 10 Medicine, Umeå University, Umeå, Sweden. ²Department of Medicine, Stanford University
- School of Medicine, Stanford, CA, USA. ³Department of Epidemiology and Population
- Health, Stanford University School of Medicine, Stanford, CA, USA. ⁴Division of Clinical
- 13 Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and
- 14 Society (NVS), Karolinska Institutet, Stockholm, Sweden . ⁵Medical Unit Aging, Karolinska
- 15 University Hospital, Stockholm, Sweden. ⁶School of Sport Sciences, UiT the Arctic
- 16 University of Norway, Tromsø, Norway. ⁷Department of Public Health and Clinical
- 17 Medicine, Section of Sustainable Health, Umeå University, Umeå, Sweden
- *Correspondence: Marcel Ballin. Unit of Geriatric Medicine, Department of Community
- 19 Medicine and Rehabilitation, Umeå University, 90187 Umeå, Sweden. Phone:
- +46735265380. E-mail: marcel.ballin@umu.se. Twitter: @Marcel Ballin
- 21 **Disclosures:** The authors received funding used for salaries from Foundation Stockholms
- 22 Sjukhem (MK), Academy of Finland (MK), Läkarsällskapet (MK), and the Swedish Research
- Council (MK, AN, PN). The funders had no role in any part of this manuscript or the decision
- 24 to publish. The authors declare no conflicts of interest. The manuscript has been submitted

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 previously as preprint in medRxiv 26 (https://www.medrxiv.org/content/10.1101/2022.03.10.22272097v2). Word count main text: 2859 27 **Abstract word count: 300** 28 Number of figures/tables: 2 figures, 1 table 29 **Impact statement:** We certify that this work is novel. This research adds to the literature by 30 31 showing there was no excess mortality observed in long-term care facility residents who survived the acute SARS-CoV-2 infection, and that life expectancy of uninfected residents 32 was much lower than that of the general population of same age and sex. This has major 33 34 repercussions for estimation of years of life lost in infected long term care facility residents. 35 **Key points** 36 SARS-CoV-2 infection sharply increased mortality risk among residents of long-term 37 care (LTC) facilities in the first month. After the first month, the mortality risk in infected residents rapidly returned to 38 baseline and dropped below the mortality risk of uninfected controls, where it 39 remained lower for 8 months of follow-up. 40 41 Median survival of uninfected controls was 1.6 years, which was much lower than national life expectancy in Sweden at age 87. 42 43 Why does this matter? Whereas LTC residents who recover from SARS-CoV-2 infection may be concerned 44 45 about having residual debilitation caused by the infection, we found no excess 46 mortality was in those who survived the acute infection. Because life expectancy of uninfected residents was much lower than that of the 47 general population of same age and sex, LTC resident status should be accounted for 48 in estimations of years of life lost. 49

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Abstract Background: SARS-CoV-2 confers high risk of short-term death in residents of long-term care (LTC) facilities, but longer-term risk among survivors is unclear. **Methods:** We extended the follow-up period of a previous, propensity score-matched retrospective cohort study based on the Swedish Senior Alert register. N=3731 LTC residents with documented SARS-CoV-2 until 15 September 2020 were matched to 3731 uninfected controls using time-dependent propensity scores on age, sex, health status, comorbidities, and prescription medications. In a sensitivity analysis, matching included also geographical region and Senior Alert registration time. The outcome was all-cause mortality over 8 months (until October 24, 2020). The absolute risk of death was examined using Kaplan-Meier plots. Hazard ratios (HR) for death over time were estimated using flexible parametric models with restricted cubic splines. Cox regression was used to estimate HRs and 95% confidence intervals (CIs) in 30-day intervals of follow-up until 210 days. **Results:** The median age was 87 years and 65% were women. Excess mortality was highest 5 days after documented infection (HR 19.1, 95% CI, 14.6-24.8), after which excess mortality decreased. From the second month onwards, mortality rate became lower in infected residents than controls. The HR for death during days 61-210 of follow-up was 0.41 in the main analysis (95% CI, 0.34-0.50) and 0.76 (95% CI, 0.62-0.93) in the sensitivity analysis. Median survival of uninfected controls was 1.6 years, which was much lower than the national life expectancy in Sweden at age 87 (5.05 years in men, 6.07 years in women). Conclusions: No excess mortality was observed in LTC residents who survived the acute SARS-CoV-2 infection. Life expectancy of uninfected residents was much lower than that of the general population of the same age and sex. This suggests that LTC resident status should be accounted for in years-of-life-lost estimates for COVID-19 burden of disease calculations.

Keywords: COVID-19, SARS-CoV-2, death, long-term care facilities, mortality

Introduction

During the coronavirus disease 2019 (COVID-19) pandemic, many of the COVID-19 deaths that occurred in high-income countries were seen in long-term care (LTC) facilities, where case fatality rates were 10-40% or even higher. We have previously reported that 30-day mortality in Swedish LTC was 40% in residents infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) versus 6% in matched, non-infected controls in the first wave of the pandemic. An atural follow-up question to ask is whether SARS-CoV-2 also increases the risk of death beyond the acute period of 30 days, i.e. whether it has long-term effects on mortality in LTC residents who recover from infection. A major concern is that LTC residents who recover from SARS-CoV-2 infection may have residual debilitation caused by the infection. If so, this may affect also their life expectancy beyond the acute phase of the infection. Moreover, it would be interesting to estimate the loss of life expectancy in LTC residents infected with SARS-CoV-2. We set out to answer these questions by extending the follow-up period in our previous analysis from 30 days to 8 months.

Methods

Study design and population

The present study offers extended follow-up on a propensity score-matched retrospective cohort study.⁴ The basic study design and of the selection of exposed (infected) and unexposed (uninfected control) residents has been described in detail previously in the publication presenting 30-days of follow-up.⁴ In brief, data on Swedish LTC residents were obtained from Senior Alert, a database of health assessments performed in older adults aged ≥65 years.⁵ All residents of LTC facilities in Sweden registered in Senior Alert were eligible to be considered. Senior Alert collects health data on various conditions in adults aged ≥65 years. Senior Alert captures an estimated 73% of all Swedish LTC facility residents. This

study was approved by the Swedish Ethical Review Authority (no. 2020-02552), which waived the informed consent requirement given the retrospective nature of the study. The study was performed in accordance with the Declaration of Helsinki.

Cohort construction and matching

We selected LTC residents who had a record in Senior Alert from 2019 or 2020; the latest record during these years was used, whenever there were multiple records. Among these, we identified 3731 LTC residents with a documented SARS-CoV-2 infection until September 15, 2020. We excluded SARS-CoV-2 infected residents that did not have a record in Senior Alert within a year prior to date of testing or confirmed infection (whichever came first or was available) and those where dates of testing and confirmed infection were both unavailable. Data on SARS-CoV-2 infections were obtained from the national SmiNet registry to which reporting is mandatory according to Swedish law.

Each infected resident was matched 1:1 to a control resident on age, sex, body mass index, health status, comorbidity, and prescription medication use, using time-dependent propensity scores. This enables matching when the exposure (date of documented SARS-CoV-2 infection) do not coincide with the time of cohort entry (date of Senior Alert record). With time starting at the date of the Senior Alert record, a Cox model calculated a propensity score for the propensity to contract SARS-CoV-2 based on all variables shown in Supplemental Table 1. Each infected resident was matched to the control with the closest propensity score among those who were still alive when the SARS-CoV-2 case occurred (counting time since the Senior Alert date). Matching was done sequentially, starting with the first case (smaller number of days since cohort entry) and proceeding with cases with increasingly larger number of days since cohort entry. Diagnoses and medications were used as time-varying covariates in the Cox regression model. Information on comorbidities was obtained from the Swedish National Patient Register and for cancer from the Swedish Cancer

Register. Information on recent use of medications (prescriptions in 2019-2020) came from Senior Alert and the Swedish Prescribed Drug Register. In addition, in order to conduct a sensitivity analysis to examine whether the results were confounded by secular trends and geographic variations in mortality, we performed an additional matching which included also the geographical region (21 categories) and the date (year and month) of Senior Alert registration. Data linkage across registers were performed using pseudo-anonymised Personal Identification Numbers.

Outcome

The study outcome was all-cause mortality (until October 24, 2020). These data were obtained from the national Swedish Cause of Death Register. While in our previous study we only assessed 30-day mortality,⁴, the extension to 8 months in the present study allows to get a more complete picture of the mortality risk of this frail population, while at the same time it largely excludes the subsequent waves and also the COVID-19 vaccination period which may have further affected mortality risk in this population.

Statistical analysis

In both the main and sensitivity analyses for death risk, all-cause mortality was considered as the outcome of interest and the starting date for follow-up was the SARS-CoV-2 documentation date in cases and the corresponding date (in days since cohort entry) in controls. Follow-up time in days was calculated as censor date (24 October 2020 or death whichever came first) minus baseline date + 1 day. This was done so that the baseline date could also be included in the follow-up time and analysis (thus, a person would be able to die on the same date as they were documented to be infected). The absolute risk of death was examined using Kaplan-Meier plots. The hazard ratio (HR) for death was plotted over time using flexible parametric models with restricted cubic splines (4 knots in default positions). HRs and 95% confidence intervals (CIs) were also estimated using Cox regression for 30-day

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

intervals of follow-up until 210 days. To adjust for matching, we calculated 95% CIs in the Cox models and the flexible parametric models using robust standard errors. All analyses were performed using Stata MP version 16.1 for Mac (StataCorp, College Station, TX). **Results Baseline characteristics** Baseline characteristics are shown in Supplemental Table 1. The median age was 87 years, 65% were women, and comorbidities were common. In the main analysis, median (interquartile range [IQR] baseline date for infected residents was 27 Apr 2020 (10 Apr to 22 May), median (maximum) follow-up was 129 (246) days and there were 1713 deaths. For controls, median (IQR) baseline date was 12 Apr 2020 (16 Dec 2019 to 30 Jun 2020), median (maximum) follow-up was 146 (641) days and there were 899 deaths. In the sensitivity analysis, for infected residents, median (IQR) baseline date was 26 Apr 2020 (IQR 10 Apr to 21 May), median (maximum) follow-up was 130 (246) days and there were 1640 deaths. For controls, median (IQR) baseline date was 28 Apr 2020 (9 Apr to 23 May), median (maximum) follow-up was 173 (249) days and there were 536 deaths. The median age was 87 years, 65% were women, and comorbidities were common (Supplemental Table 1). **Mortality analyses** As previously reported, SARS-CoV-2 was associated with a sharp, early increased risk of death: 40% versus 6% within 30 days (1487/3731 versus 211/3731). However, extending the follow-up period showed that the risk soon plateaued (Figure 1A). Similar results were seen in the sensitivity analysis (Figure 1B). Survival of controls at 210 days was 74.3% (72.6%-75.9%) in the main analysis and 82.9% (81.3%-84.4%) in the sensitivity analysis. Median survival of controls was 577 days. Median survival was also 577 days among the controls who were matched to the 1487 infected residents who died in the first month. Survival of these 1487 controls was similar to

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

the survival of the remaining 2242 controls, for example their survival at 210 days was 72.5% versus 75.4%. In the main analysis, peak HR (19.1 (95% CI, 14.6-24.8)) occurred at 5 days after documented infection. HR was high in the first month, decreased below 1.0 early in the second month, and remained below 1.0 for the remaining duration of follow-up (Figure 2a). In the sensitivity analysis, peak HR was 21.5 (95% CI, 15.9-29.2). Again, HR decreased sharply but took a bit longer to drop below 1.0 (after the second month) and remained below 1.0 afterwards (Figure 2b). In the main analysis, for 0-30 days, there were 1487 deaths among infected residents (17.57 deaths per 1000 person-days) versus 211 in uninfected controls (1.88 deaths per 1000 person-days), resulting in a HR of 8.81 (7.64-10.15). For 31-60 days, there were 93 deaths (1.42 per 1000 person-days) versus 144 (1.42 per 1000 person-days) (HR 1.00 (0.77-1.30)). For 61-90 days the respective numbers were 33 (0.55) versus 121 (1.38) (HR 0.38 (0.26-0.55)). For 91-120 days, the respective numbers were 38 (0.63) versus 126 (1.72) (HR 0.36 (0.25-0.52)). A similar pattern was seen for 121-150 days (HR, 0.52 (0.36-0.76)), 151-180 days (HR 0.47 (0.28-0.79)), and 181-210 days (HR 0.29 (0.10-0.83)). During the 61-210 days follow-up, there were 133 deaths among infected residents (0.58 per 1000 person-days) versus 420 deaths among the uninfected controls (1.37 per 1000 person-days), with the HR being 0.41 (0.34-0.50). In the sensitivity analysis, during 61-210 days of follow-up, there were 131 deaths (0.59 per 1000 person-days) in infected versus 278 deaths (0.78 per 1000 person-days) in controls, with the HR being 0.76, 95% CI, 0.62-0.93). **Discussion** In this extended follow-up analysis of mortality in SARS-CoV-2-infected versus uninfected control LTC residents, we found that mortality risk peaked during the first week of

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

documented infection, after which it rapidly decreased. Mortality remained elevated for the first month after infection, but then reverted back to baseline levels (i.e., control levels) before it dropped below baseline levels, where it remained at low levels for the remaining duration of follow-up (up to 8 months). These results suggest that SARS-CoV-2 does not reduce the life expectancy of LTC residents who survive the acute period of the disease. Despite concerns that infected residents who survive may have persistent residual debilitation that might enhance their subsequent death risk, we saw the opposite: death risk decreased in longer-term follow-up. This suggests that deaths due to COVID-19 in LTC facilities in Sweden during the first wave probably resulted in average loss of life expectancy of less than 1.6 years on average. This figure is much lower than the life expectancy in the general Swedish population, which in 2019 was 5.05 years for men and 6.07 years for women at the age of 87 (the median age in our study).⁷ Calculations of burden of disease due to COVID-19 often use age- and sexadjusted life expectancies to calculate years-of-life-lost; however, without properly accounting for LTC residence and general health. Our findings suggest that such an approach can yield massively inflated estimates. 8 Adjustment for comorbidities has been shown to decrease the number of years-of-life-lost in some studies. 9-11 However, the change is typically modest (e.g. in the range of 1 years) and much smaller than what we observed in the LTC resident population that we evaluated. It is possible that in most studies, information on comorbidities is not available in sufficient granularity and accuracy regarding severity. E.g. "kidney disease" would carry very different risk connotations depending on the stage and severity. LTC resident status is a surrogate for increased frequency and severity of many comorbidities and of overall frailty. Therefore, it should be taken into account as a first correction for any years-of-life-lost estimates for COVID-19 burden of disease calculations.

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

Calculations accounting for LTC status and also properly adjusting for comorbidities and their severity may also lead to much lower estimates than some other increasingly used approaches such as the Global Burden of Disease Reference Life Table 12 also known as Theoretical Minimum Risk Life Table. This life table is an "aspirational" construct: it assumes an idealized situation with very low risk of death. According to this table, life expectancy is 88.9 years at birth, 9.99 years at age 85, 5.92 years at age 90, and 5.92 years at age 95.13 Using this popular aspirational life table would probably overestimate by 5-10-fold the years-of-life-lost for SARS-CoV-2-deceased residents in LTC facilities. Aspirational life tables have been promoted as a way to standardize burden of disease calculations across different countries. However, in the case of diseases like COVID-19 they could lead to grossly misleading inferences. Estimates of survival in residents of LTC facilities preceding the COVID-19 pandemic also agree with very limited median survival of nursing home residents, e.g. 541 days in one study in the United Kingdom¹⁴ and 2 years in a study of residential care entrants in New Zealand. 15 In Sweden, previously published data 16 on the survival of elderly people who moved into institutionalized care in an area of Stockholm (N=1103) suggested that, on average, the median survival after moving to institutionalized care declined between 2006 and 2012 from 764 to 595 days. For the lower percentiles, the decrease was very large, e.g. for the 30th percentile, the length of stay declined from 335 days in 2006 to 119 days in 2012, and in 2012 10% died within just 8 days. A widening survival gap (due to shortening survival in nursing home residents) versus community-dwelling elderly has also been documented in a 10-year study in England.¹⁷ Another study¹⁸ evaluated all deaths in people >67 years old in November 2015 in Sweden and focused on the 2 years prior to death. Women used LTC for 15.6 months and men for 14.1 months out of 24 these months. The length of stay in institutional care was 7.2 and 6.2 months, respectively. These survival data for LTC residents

are in line with the estimated median survival of controls in our study, thus further validating the median survival in residents of LTC facilities is very limited.

We should acknowledge that there can be large heterogeneity in survival in different LTC facilities. Some LTC facilities admit mostly residents with known limited life-expectancy (mostly for palliative care), while others may be institutions that admit mostly older adults who are quite healthy or have limited health problems with substantial life-expectancy. A systematic review has found that across 6 cohort studies, the mortality rate within 6 months of admission to a nursing home ranged from 0% to 34% (median 20.2%). In our analysis, we could not include data on the features of each LTC facility (e.g. whether it focused on palliative care) and we could not match infected residents with uninfected residents from the same facility. Nevertheless, the control groups both in the main and in the sensitivity analysis seem to have median survival that is entirely compatible with the literature on LTC residents and their overall limited expected survival, on average.

Some additional caveats should be discussed. Our data pertain to fatalities during the first wave of COVID-19 and until the fall of 2020. The first wave was the most devastating in most high-income countries, with a few exceptions (e.g. Australia). The relatively lower proportion of fatalities in LTC residents in subsequent waves may reflect a combination of multiple factors: high levels of prior infection (seroprevalence studies have found 5-10 times higher infection rates in LTC facilities than in the general population in the first wave), 22-24 better protection of nursing homes, more extensive testing, widespread use of vaccination in 2021, and the possibility that the sickest individuals were the first to succumb. Moreover, the lower risk of death after the first month post-infection versus the uninfected controls should not be interpreted as a sign that SARS-COV-2 infection causally decreases the risk of death during long-term follow-up, as it probably reflects mostly a selection process (residents who died in the first month were probably more sick and

debilitated before infection, while those surviving probably had better life expectancy). Finally, we cannot exclude the possibility that some controls may have been asymptomatically infected but the infection remained unnoticed due to limited testing, especially in the early weeks of the pandemic. With more systematic testing after the end of the first wave and with limited epidemic activity during the late spring and summer of 2020, it is unlikely that infections in controls were missed in that period, let alone that these infections would shorten the survival of the control groups. As above, the observed limited survival of the control groups is entirely in line with data on residents of LTC facilities in the absence of COVID-19 from Sweden and elsewhere. In further support of our findings, excess death calculations for Sweden for 2020 and also for the entire pandemic period to end of 2021 and early 2022 show very limited excess deaths, if at all. ^{26,27} This pattern is entirely congruent with the possibility that many/most residents who died of SARS-CoV-2 in the first wave had very limited life expectancy. Therefore, they would not contribute to excess death calculations, if excess deaths are assessed over 1-2 years downstream. Allowing for these caveats, the major strength of our study is that it uses on large databases with nationwide coverage. Even so, similar analyses should also be performed in other countries because the health status of LTC residents may be different and with assessments covering also the vaccination period for a complete picture of the COVID-19 pandemic.²⁸ This will allow to obtain more solid evidence on both the years-of-life-lost over 2020-2022, as well as insights about the long-term outcomes of SARS-CoV-2-infected residents of various types of LTC facilities who survived and recovered from the acute

Acknowledgments

infection.

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

Conflict of Interest: The authors received funding used for salaries from Foundation Stockholms Sjukhem (MK), Academy of Finland (MK), Läkarsällskapet (MK), and the Swedish Research Council (MK, AN, PN). The authors declare no conflicts of interest. Author Contributions: Concept and design: MB, JPI, JB, PN, Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: MB, JPI. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: MB and JB. Supervision: PN, JPI. Sponsor's Role: The funders had no role in any part of this manuscript or the decision to publish. References 1. Comas-Herrera A, Zalakaín J, Lemmon E, Henderson D, Litwin C, Hsu A, et al. Mortality associated with COVID-19 in care homes: international evidence. Article in LTCcovid.org, International Long-Term Care Policy Network, CPEC-LSE, 14 October2020. 2. Panagiotou OA, Kosar CM, White EM, et al. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. JAMA Intern Med. 2021; 181: 439-448. 3. Murti M, Goetz M, Saunders A, Sunil V, Guthrie JL, Eshaghi A, Zittermann S, Teatero S, Fittipaldi N, Rilkoff H, Gubbay JB, Garber G, Callery S, Holt AM, Noseworthy AL. Investigation of a severe SARS-CoV-2 outbreak in a long-term care home early in the pandemic. CMAJ. 2021 May 10;193(19):E681-E688. 4. Ballin M, Bergman J, Kivipelto M, Nordström A, Nordström P. Excess Mortality After COVID-19 in Swedish Long-Term Care Facilities. J Am Med Dir Assoc. 2021 Aug;22(8):1574-1580.e8.

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

5. Edvinsson J, Rahm M, Trinks A, Hoglund PJ. Senior alert: A quality registry to support a standardized, structured, and systematic preventive care process for older adults. Qual Manag Health Care. 2015;24:96–101. 6. Brooke HL, Talbäck M, Hörnblad J. The Swedish cause of death register. Eur J Epidemiol. 2017;32:765-773. 7. https://www.statistikdatabasen.scb.se/pxweb/en/ssd/START BE BE0101 BE010 1I/LivslangdEttariga/, last accessed March 3, 2022 8. Ioannidis JPA. Over- and under-estimation of COVID-19 deaths. Eur J Epidemiol. 2021 Jun;36(6):581-588. 9. Ferenci T. Different approaches to quantify years of life lost from COVID-19. Eur J Epidemiol. 2021;36:589-597. 10. von der Lippe E, Devleesschauwer B, Gourley M, et al. Reflections on key methodological decisions in national burden of disease assessments. Arch Public Health. 2020;78:137. 11. Hanlon P, Chadwick F, Shah A, et al. COVID-19—exploring the implications of longterm condition type and extent of multimorbidity on years of life lost: a modelling study. Wellcome Open Res 2021;5:75. 12. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396:1204-1222. 13. Global Burden of Disease Study 2019 Reference Life Table, http://ghdx.healthdata.org/record/ihme-data/global-burden-disease-study-2019-gbd-2019-reference-life-table, last accessed March 8, 2022.

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

14. Rothera IC, Jones R, Harwood R, Avery AJ, Waite J. Survival in a cohort of social services placements in nursing and residential homes: factors associated with life expectancy and mortality. Public Health. 2002 May;116(3):160-5. 15. Broad JB, Lumley T, Ashton T, Davis PB, Boyd M, Connolly MJ. Transitions to and from long-term care facilities and length of completed stay: Reuse of population-based survey data. Australas J Ageing. 2017 Jun;36(2):E1-E7. 16. Schön P, Lagergren M, Kåreholt I. Rapid decrease in length of stay in institutional care for older people in Sweden between 2006 and 2012: results from a populationbased study. Health Soc Care Community. 2016 Sep;24(5):631-8. 17. Espuny Pujol F, Hancock R, Morciano M. Trends in survival of older care home residents in England: A 10-year multi-cohort study. Soc Sci Med. 2021 Aug;282:113883. 18. Meinow B, Wastesson JW, Kåreholt I, Kelfve S. Long-term care use during the last 2 years of life in Sweden: implications for policy to address increased population aging. J Am Med Dir Assoc. 2020 Jun;21(6):799-805. 19. Ferrah N, Ibrahim JE, Kipsaina C, Bugeja L. Death following recent admission into nursing home from community living: A systematic review into the transition process. J Aging Health. 2018 Apr;30(4):584-604. 20. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Second versus first wave of COVID-19 deaths: Shifts in age distribution and in nursing home fatalities. Environ Res. 2021 Apr;195:110856. 21. Pastorino R, Pezzullo AM, Villani L, Causio FA, Axfors C, Contopoulos-Ioannidis DG, Boccia S, Ioannidis JPA. Change in age distribution of COVID-19 deaths with the introduction of COVID-19 vaccination. Environ Res. 2022 Mar;204(Pt C):112342.

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

22. Candel FJ, Barreiro P, San Román J, Del Mar Carretero M, Sanz JC, Pérez-Abeledo M, et al. The demography and characteristics of SARS-CoV-2 seropositive residents and staff of nursing homes for older adults in the Community of Madrid: the SeroSOS study. Age Ageing. 2021;50(4):1038-47. 23. Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. J Clin Med. 2020;9(9). 24. Krutikov M, Palmer T, Tut G, Fuller C, Shrotri M, Williams H, et al. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. Lancet Healthy Longevity. 2021;2(6):e362-e70. 25. Levi M, Cipriani F, Romeo G, Balzi D. Analysis of the excess mortality and factors associated with deaths from COVID-19 versus other causes in Central Tuscany (Italy) in 2020. Epidemiol Prev. 2021 Nov-Dec;45(6):496-503. 26. Kowall B, Standl F, Oesterling F, Brune B, Brinkmann M, Dudda M, Pflaumer P, Jöckel KH, Stang A. Excess mortality due to Covid-19? A comparison of total mortality in 2020 with total mortality in 2016 to 2019 in Germany, Sweden and Spain. PLoS One. 2021 Aug 3;16(8):e0255540. 27. Human Mortality Database, mortality.org, last accessed May 1, 2022. 28. Ioannidis JP. The end of the COVID-19 pandemic. Eur J Clin Invest 2022; Mar 28:e13782. Figure legends: Figure 1. Risk of death in residents with SARS-CoV-2 and controls in the main analysis (A) and in the sensitivity analysis (B). The coloured areas show the 95% confidence interval.

Figure 2. Hazard ratio for death in residents with SARS-CoV-2, as compared with controls in

(A) the main analysis and (B) the sensitivity analysis. The coloured areas show the 95%

confidence interval

394

395

396



